Investors & Media

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases and disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB).

We released topline results from three pivotal Phase 3 clinical trials for the treatment of H. pylori infection, the treatment of erosive GERD, and the treatment of symptomatic non-erosive GERD.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.